Showing results (871-880 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology|November 11, 2018
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trialMette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, et al.
The Lancet. Oncology|November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort studyMartin H Voss, Albert Reising, Yuan Cheng, et al.
The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology|March 20, 2019
Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort studyOsama Mohamad, Takahiro Tabuchi, Yuki Nitta, et al.
The Lancet. Oncology|September 9, 2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Francesco Schettini, Carla Rognoni, et al.
The Lancet. Oncology|October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trialAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
The Lancet. Oncology|October 4, 2019
Access to radiotherapy among circumpolar Inuit populationsJessica Chan, Jeppe Friborg, Mikhail Chernov, et al.
The Lancet. Oncology|October 5, 2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyCarmen D Herling, Kevin R Coombes, Axel Benner, et al.
Pageof 338